Provided by Tiger Trade Technology Pte. Ltd.

Greenwich Lifesciences Inc

16.67
+1.368.88%
Post-market: 16.63-0.0420-0.25%19:56 EDT
Volume:176.79K
Turnover:2.96M
Market Cap:244.69M
PE:-10.56
High:17.48
Open:16.16
Low:15.54
Close:15.31
52wk High:34.10
52wk Low:7.78
Shares:14.68M
Float Shares:7.65M
Volume Ratio:1.46
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5783
EPS(LYR):-1.4302
ROE:-986.32%
ROA:-235.98%
PB:78.50
PE(LYR):-11.66

Loading ...

Company Profile

Company Name:
Greenwich Lifesciences Inc
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
- -
Office Location:
Building 14,3992 Bluebonnet Dr.,Stafford,Texas,United States
Zip Code:
77477
Fax:
- -
Introduction:
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Directors

Name
Position
David McWilliams
Chairman of the Board and Director
Snehal Patel
Chief Executive Officer and Chief Financial Officer and Director
F. Joseph Daugherty
Chief Medical Officer and Director
Eric Rothe
Director
Kenneth Hallock
Director

Shareholders

Name
Position
Snehal Patel
Chief Executive Officer and Chief Financial Officer and Director
F. Joseph Daugherty
Chief Medical Officer and Director
Jaye Thompson
Vice President Clinical & Regulatory Affairs